SynthesisInternational journal of clinical oncology2026
KEAP1 promoter hypermethylation in human cancers: a meta-analysis of case-control studies.
Synthesis in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKelch-like ECH-associated protein 1 (KEAP1) regulates the NRF2 signaling pathway and plays a critical role in oxidative stress response and tumor suppression. Promoter hypermethylation of KEAP1 may contribute to carcinogenesis; however, its association with cancer remains unclear.
methodsA systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. PubMed, Scopus, Web of Science, and the Cochrane Library were searched up to July 29, 2025. Eligible case-control studies were included. Pooled odds ratios (ORs) were calculated using a random-effects model. Heterogeneity, subgroup effects, publication bias, and robustness were assessed using standard meta-analytic approaches.
resultsSeven studies comprising 407 cancer cases and 158 controls were included. KEAP1 promoter hypermethylation was significantly associated with cancer presence (OR = 13.66; 95% CI 4.89-38.14; p < 0.001), with moderate heterogeneity (I² = 42.1%). Subgroup analyses indicated that heterogeneity was largely explained by cancer type and methylation detection method, with strong associations observed in lung and other cancers but not in colorectal cancer. Studies using qMSP showed more consistent and stronger effects than MSP-based studies. Publication bias was suggested by Egger's test (p = 0.006), and trim-and-fill analysis indicated potential overestimation of the pooled effect. Sensitivity analyses using the Hartung-Knapp-Sidik-Jonkman and GLMM approaches supported the robustness of the findings.
conclusionKEAP1 promoter hypermethylation is significantly associated with cancer in case-control studies. Although findings were consistent across multiple analyses, potential bias and limited study numbers warrant cautious interpretation.
Indexed as
Identifiers
42250140What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.